PUBLICATIONS · 1569443
Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 1992 May
- First author
- Alberts DS
This record carries publication-notice metadata. Review the notices below before relying on it.
Publication notices
- absence is not clearance
- true
- has correction metadata
- true
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- citation
- J Clin Oncol 1992 Sep;10(9):1505
- note
- Source null
- related pmid
- Source null
- relationship
- Erratum in
- url
- Source null
- citation
- J Clin Oncol. 1992 May;10(5):683-5. doi: 10.1200/JCO.1992.10.5.683.
- note
- Source null
- related pmid
- 1569441
- relationship
- Comment in
Authors and identifiers
- name
- Alberts DS
- type
- Author
- name
- Green S
- type
- Author
- name
- Hannigan EV
- type
- Author
- name
- O'Toole R
- type
- Author
- name
- Stock-Novack D
- type
- Author
- name
- Anderson P
- type
- Author
- name
- Surwit EA
- type
- Author
- name
- Malvlya VK
- type
- Author
- name
- Nahhas WA
- type
- Author
- name
- Jolles CJ
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Alberts DS
- type
- Author
- name
- Green S
- type
- Author
- name
- Hannigan EV
- type
- Author
- name
- O'Toole R
- type
- Author
- name
- Stock-Novack D
- type
- Author
- name
- Anderson P
- type
- Author
- name
- Surwit EA
- type
- Author
- name
- Malvlya VK
- type
- Author
- name
- Nahhas WA
- type
- Author
- name
- Jolles CJ
- type
- Author
- bibliography ids
- nci-bib-9f0a63b0c43556a6f187ba04
- book metadata
- content sha256
- fd6fa06507ce84f5c84a36ccdac39320077b40e5b4da212f3e3d54ed8fec7663
- document type
- citation
- dois
- 10.1200/JCO.1992.10.5.706
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:1569443
- immutable id
- pubmed:1569443@fd6fa06507ce84f5c84a36ccdac39320077b40e5b4da212f3e3d54ed8fec7663
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- Source null
- issn print
- 0732-183X
- issue
- 5
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 706-17
- volume
- 10
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- true
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- citation
- J Clin Oncol 1992 Sep;10(9):1505
- note
- Source null
- related pmid
- Source null
- relationship
- Erratum in
- url
- Source null
- citation
- J Clin Oncol. 1992 May;10(5):683-5. doi: 10.1200/JCO.1992.10.5.683.
- note
- Source null
- related pmid
- 1569441
- relationship
- Comment in
- outcomes validated
- false
- pmid
- 1569443
- provenance
- batch id
- 4dd31a34efbe4b9fe1c1
- provider
- NCBI PubMed ESummary
- record sha256
- 232f0f3d4c2cb4fbf34813534a2a4f01058d88c993aa435ccd482060d8e65299
- response sha256
- 6a38fb0063e4902598a1efcc0d1821501cf82821747967b29fe13940a1d400ba
- retrieved at
- 2026-09-09T23:45:07.034965+00:00
- publication date
- display
- 1992 May
- precision
- month
- year
- 1992
- publication types
- Clinical Trial
- Comparative Study
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, P.H.S.
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- source url
- https://pubmed.ncbi.nlm.nih.gov/1569443/
- title
- Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.
Preserved source evidence · Not medical advice
Triangle